Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose vaccine was authorized for emergency use in December for individuals age 18 and older, said its trial data shows that its vaccine is 96% effective in 12 to 17 year-olds who received at least one injection.  

Moderna yesterday announced that its vaccine booster, which remains in a phase 2 clinical trial, showed positive immune response for several COVID-19 variants, including those first discovered in South Africa and Brazil. The booster is intended for administration in patients who already completed the standard, two-dose regimen.

 

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The Centers for Disease Control and Prevention today revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19…
Headline
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response this week announced a major change in the distribution of…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first…
Headline
State and territorial health departments have resumed distributing monoclonal antibodies to clinical sites, the Department of Health and Human Services…